Get started
Author

Ying Cheng

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
2024 · Ying Cheng, David R. Spigel, et al. · New England Journal of Medicine · 402
PDF
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
2024 · HARMONi-A Study Investigators, Wenfeng Fang, et al. · JAMA · 235
PDF
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
2024 · Ying Cheng, Yun Fan, et al. · Journal of Thoracic Oncology · 174
PDF
Iron promotes both ferroptosis and necroptosis in the early stage of reperfusion in ischemic stroke
2024 · Bin Du, Zijie Deng, et al. · Genes & Diseases · 51
A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
2022 · Jian Li, Jun Zhao, et al. · Journal of Clinical Oncology · 37
Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.
2022 · Ying Cheng, Liang Han, et al. · Journal of Clinical Oncology · 34
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer
2024 · Jiachen Xu, Rui Wan, et al. · Cancer Cell · 33
Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
2022 · Shukui Qin, Yuxian Bai, et al. · Journal of Clinical Oncology · 28
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial
2026 · Jianchun Duan, Yuping Sun, et al. · Cancer Cell · 25
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
2022 · Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, et al. · Journal of Clinical Oncology · 23
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial
2024 · Zi-Xian Wang, Junjie Peng, et al. · Med · 22
PDF
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer
2024 · Panpan Zhang, Zhendong Chen, et al. · Cancer Immunology Immunotherapy · 21
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors
2024 · Jian Li, Ye Xu, et al. · Chinese Journal of Cancer Research · 21
Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial
2024 · Ying Cheng, Lin Wu, et al. · Cancer Research · 20
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
2026 · Liang Zhang, Xiqin Zhang, et al. · The Lancet Oncology · 14
Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.
2022 · Pasi A. Janne, Mengzhao Wang, et al. · Journal of Clinical Oncology · 14
A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.
2024 · Chunjiao Wu, Dongqing Lv, et al. · Journal of Clinical Oncology · 11
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
2024 · Jin-Ji Yang, Jianying Zhou, et al. · The Lancet Respiratory Medicine · 10
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
2023 · Lin Shen, Yuxian Bai, et al. · Journal of Clinical Oncology · 10
PDF
Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC).
2023 · Ying Cheng, Jie Wang, et al. · Journal of Clinical Oncology · 9
PDF
Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
2017 · Tony Mok, Ying Cheng, et al. · Journal of Clinical Oncology · 9
Exploring anxiolytic peptides derived from walnut protein by an integrated approach of multivariate analysis, random forest methodology
2025 · Zishan Hong, Ying Cheng, et al. · Food Bioscience · 8
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
2025 · Lin Shen, Yuxian Bai, et al. · Journal of Clinical Oncology · 8
PDF
Quercetin can improve anesthesia induced neuroinflammation and cognitive dysfunction by regulating miR-138-5p/ LCN2
2025 · Linjie Lou, Wanning Yu, et al. · BMC Anesthesiology · 8
PDF
Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.
2024 · Ying Cheng, Liang Han, et al. · Journal of Clinical Oncology · 8
PDF
Works count: 81
Citation count: 1,391
H-index: 14
I10-index: 19
Year
Topic
Type